AwardedPOLGoods
Sukcesywna dostawa produktu leczniczego zawierającego w swoim składzie substancję czynną niwolumab w ramach realizacji niekomercyjnego badania klinicznego: ,,Efficacy and Tolerability of N-AVD compared to BrECADD in patients with advanced Hodgkin Lymphoma (N-BRAVE)"
- Published
- Published 16 April 2026
- Deadline
- Closed 27 May 2026
Overview
Gdański Uniwersytet Medyczny awarded a contract to Urtica Sp. z o.o. on 28 May 2026 for the successive supply of the pharmaceutical product containing the active substance nivolumab to clinical research centers conducting the non-commercial clinical trial "N-BRAVE" (Efficacy and Tolerability of N-AVD compared to BrECADD in patients with advanced Hodgkin Lymphoma), funded under the Polish Medical Research Agency's oncology research competition. The contract value is 26,393,469 PLN, with the quantity of drug packages subject to reduction by up to 95% based on the buyer's needs without requiring contract amendment.
Key details
- Country
- POL
- Status
- Awarded
- Category
- Goods
- Procedure
- Open
- Published
- 16 April 2026
- Deadline
- Closed
Pharmaceutical products
Award outcome
- Awarded value
- PLN 26,393,469
- Award date
- 28 May 2026
- Contract period
- 1 June 2026 → 31 May 2031
- Urtica Sp. z o.o.
Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.
Notice history
Every published notice in this contracting process, newest first.
Contract Award Notice
22 June 2026
Contract Notice
12 May 2026
Contract Notice
16 April 2026
Contracting authority
Gdański Uniwersytet Medyczny
Procuring entityGdańsk, POL
Get the full picture
AI analysis, bid scoring, and expert strategy for this tender
Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.
See which competitors are winning the contracts you're chasing.
15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.